Sanofi India wins tax appeal, demand of ₹72.71 lakh deleted

1 min read     Updated on 03 Jul 2026, 11:25 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Sanofi India received a favourable order from the Commissioner of Income Tax Appeal (CIT) - 49, Mumbai, deleting a tax demand of ₹72.71 lakh for Assessment Year 2019-20. The order accepted the company's submission that it cannot be treated as an 'assessee in default' under Section 201(1) of the Income-tax Act, 1961, after making a disallowance in its tax computation. There is no material impact on the company's financial, operational, or other activities.

powered bylight_fuzz_icon
44603676

*this image is generated using AI for illustrative purposes only.

Sanofi India Limited has secured a favourable order from the Income Tax Department, resulting in the deletion of a tax demand of ₹72.71 lakh for Assessment Year 2019-20. The order was issued by the Office of the Commissioner of Income Tax Appeal (CIT) - 49, Mumbai, on July 02, 2026. The authority accepted the company's submissions regarding the tax treatment of year-end provisions, concluding that the company cannot be treated as an 'assessee in default' under Section 201(1) of the Income-tax Act, 1961, for the same amount already disallowed in its tax computation.

Background of the Appeal

The dispute arose from an order issued under Section 201 of the Income-tax Act, which treated the company as an assessee in default for non-deduction of taxes on year-end provisions. This determination had led to a demand of ₹72.71 lakh. Sanofi India had filed an appeal against this order, arguing that the disallowance made in its tax computation precluded the additional demand and interest under the default assessee provisions.

Key Details of the Order

The Commissioner of Income Tax Appeal ruled that once the company made the disallowance, the proceedings initiated under Section 201 were not maintainable. Consequently, the demand and associated interest were dropped. The table below summarizes the key aspects of the regulatory disclosure:

Detail Description
Name of the authority Income Tax Department- Office of the Commissioner of Income tax Appeal - 49, Mumbai
Nature of action Favourable order dropping proceedings under Section 201 of the Income-tax Act, 1961
Demand deleted ₹72.71 lakh
Assessment Year 2019-20
Date of receipt July 02, 2026

Financial Impact

Sanofi India stated that there is no material impact on its financial, operational, or other activities as a result of this order. The resolution of this tax dispute removes the liability associated with the previous demand.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-1.42%+2.07%+8.07%-17.31%-43.85%-55.51%

Will this legal precedent influence Sanofi India's strategy for handling year-end provisions in future tax filings?

Does this favorable order signal a potential shift in the Income Tax Department's approach to similar Section 201 disputes?

Are there other pending tax litigations for different assessment years that could benefit from this ruling?

Sanofi releases aide-mémoire for Q2 2026 results

0 min read     Updated on 01 Jul 2026, 11:07 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Sanofi released the aide-mémoire for its Q2 2026 results on July 1, 2026, covering non-comparable items, foreign currency impact, and share count. The document aids financial modelling prior to the full results publication. Sanofi will publish its Q2 2026 results on July 30, 2026.

powered bylight_fuzz_icon
44429849

*this image is generated using AI for illustrative purposes only.

Sanofi released the aide-mémoire for its second quarter 2026 results on July 1, 2026, providing investors with data to support financial modelling ahead of the full earnings publication. The document, available on the Investors page of sanofi.com, details non-comparable items, foreign currency impact, and share count. The company is scheduled to publish its Q2 2026 results on July 30, 2026.

Key Details

The aide-mémoire is prepared each quarter to assist analysts and investors in modelling the company's financial performance. It focuses on specific adjustments and metrics that may affect comparability.

Component Description
Non-comparable items Items affecting period-over-period comparison
Foreign currency impact Effects of currency fluctuations
Share count Number of shares outstanding

Publication Schedule

Sanofi will release the complete financial results for the second quarter of 2026 on July 30, 2026. The company is listed on EURONEXT: SAN and NASDAQ: SNY.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-1.42%+2.07%+8.07%-17.31%-43.85%-55.51%

What are the anticipated non-comparable items for Q2 2026, and how might they influence year-over-year comparisons?

How could recent foreign currency fluctuations impact Sanofi's Q2 2026 revenue and profitability?

What changes in share count are expected, and what might they indicate about the company's buyback or issuance strategy?

More News on Sanofi

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-43.85%